RTGN RetinalGenix Technologies Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1836295 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-34,441.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets46,768.1%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-26,393.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $111,573 | $66,406 | $117,064 | $34,942 | $20,454 | $14,430 | $13,214 | $104,271 |
| SG&A expense | $275,407 | $212,254 | $262,149 | $305,871 | $270,153 | $383,729 | $341,203 | $392,109 |
| Interest expense | $1,525 | $3,955 | $1,260 | $1,068 | $958 | $1,070 | $909 | $960 |
| Net income | -$433,025 | -$307,397 | -$590,489 | -$623,127 | -$568,791 | -$649,418 | -$587,259 | -$867,027 |
| EPS (basic) | -0.02 | -0.02 | -0.03 | — | -0.03 | -0.03 | -0.03 | — |
| EPS (diluted) | -0.02 | -0.02 | -0.03 | — | -0.03 | -0.03 | -0.03 | — |
| Weighted avg. shares (diluted) | 19.07M | 18.81M | 18.75M | — | 18.58M | 18.33M | 18.52M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5 | $27,232 | $180 | $14,774 | $92 | $839 | $3,711 | $6,060 |
| Current assets | $5 | $27,232 | $180 | $14,774 | $92 | $839 | $3,711 | $6,060 |
| PP&E, net | — | — | — | — | — | — | $31 | $56 |
| Total assets | $4,346 | $32,215 | $5,805 | $21,041 | $7,001 | $8,388 | $11,931 | $14,946 |
| Current liabilities | $2.03M | $2.67M | $2.56M | $2.32M | $2.17M | $1.98M | $1.67M | $1.47M |
| Total liabilities | $2.03M | $2.67M | $2.56M | $2.32M | $2.18M | $1.99M | $1.68M | $1.48M |
| Shareholders' equity | -$2.03M | -$2.64M | -$2.56M | -$2.30M | -$2.17M | -$1.98M | -$1.67M | -$1.46M |
| Shares outstanding | 19.29M | 18.84M | 18.75M | 18.75M | 18.60M | 18.56M | 18.52M | 18.52M |
| Cash flow statement | ||||||||
| Operating cash flow | -$82,484 | -$136,671 | -$109,213 | -$128,219 | -$103,837 | -$139,072 | -$187,222 | -$186,390 |
| Financing cash flow | $55,257 | $163,723 | $94,619 | $142,901 | $103,090 | $136,200 | $184,873 | $113,361 |
| Depreciation & amortization | — | — | — | $0 | $0 | $31 | $25 | $25 |
| Stock-based compensation | $44,520 | $24,782 | $210,016 | $281,246 | $277,226 | $250,189 | $231,933 | $369,687 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.